Acinetobacter baumannii bacteremia: Clinical and prognostic features;Bacteriemias por Acinetobacter baumannii: Características clínicas y pronósticas

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 21, Issue 5, 2003, Pages 242-247

  Rodríguez Baño, Jesús ^a   Pascual, Álvaro ^a   Gálvez, Juan ^a   Muniain, Miguel Ángel ^a   Ríos, Ma José ^a   Martínez Martínez, Luis ^a   Pérez Cano, Ramón ^a   Perea, Evelio J ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

Author keywords

Acinetobacter baumannii; Bacteriemia; Nosocomial infection

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZTREONAM; CEFOTAXIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; IMIPENEM; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TICARCILLIN; TOBRAMYCIN;

ACINETOBACTER BAUMANNII; ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; BACTERIUM IDENTIFICATION; CHRONIC DISEASE; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG CHOICE; FEMALE; HILF SEVERITY SCORE; HOSPITAL INFECTION; HUMAN; INCIDENCE; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIDRUG RESISTANCE; MULTIVARIATE ANALYSIS; PATIENT CARE; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; SEPTIC SHOCK; STRAIN IDENTIFICATION; SURGICAL RISK;

EID: 0038121037     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13046543     Document Type: Article

References (43)

1. Bergone-Berezéin E. The increasing significance of Acinetobacter spp.: The need for control and new agents. J Hosp Infect 1995;30(Suppl):441-2.
2. Bergone-Berezéin E, Towner KJ. Acinetobacter spp. As nosocomial pathogens: Microbiological, clinical and epidemiological features. Clin Microb Rev 1996;9:148-5.
3. Cisneros JM, Reyes MJ, Pachón J, Becerril B, Caballero FJ, García-Garmendia JL, et al. Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings and prognostics features. Clin Infect Dis 1996;22:1026-32.
4. Fagon JY, Chastre J, Domart Y, Trouillet JL, Gibert C. Mortality due to ventilator-associated pneumonia or colonization with Pseudomonas aeruginosa or Acinetobacter species: Assessment by quantitative culture of samples obtained by protected specimen brush. Clin Infect Dis 1996;23:538-42.
5. Smego RA. Endemic nosocomial Acinetobacter calcoaceticus bacteraemia. Clinical significance, treatment, and prognosis. Arch Intern Med 1985;145:2174-9.
6. Tilley PAG, Roberts FJ. Bacteremia with Acinetobacter species: Risk factors and prognosis in different clinical settings. Clin Infect Dis 1994;18:896-900.
7. Bouvet PJM, Grimont PAD. Taxonomy of the genus Acinetobacter with the reeognition of Acinetobacter baumannii sp. nov., Acinetobacter haemolyticus sp. nov., Acinetobacter johnsonii sp. nov., and Acinetobacter junii sp. nov. and emendeded descriptions of Acinetobacter calcoaceticus and Acinetobacter lwofii. Inter J Sys Bacteriol 1986;36:228-40.
8. Seifert H, Strate A, Schultze A, Pulverer G. Bacteremia due to Acinetobacter spp. others than Acinetobacter baumannii. Infection 1994;6:379-85.
9. Berlau J, Aucken H, Malmick H, Pitt T. Distribution of Acinetobacter species on skin of healthty human. Eur J Clin Microbiol Infect Dis 1999;18:179-83.
10. Seifert H, Strate A, Pulverer G. Nosocomial bacteremia due to Acinetobacter baumannii. Clinical features, epidemiology, and presdictors of mortality. Medicine (Baltimore) 1995;74:340-9.
11. American College of Chest Physichians/Society of Critical Care Medicine. Consensus conference committee. Definitions for sepsis and organ failure and guidelines for use of innovative therapies in sepsis. Crit Care Med 1992; 20:864-74.
12. McCabe WR, Jackson GG. Gram negative bacteremia I. Etiology and ecology. Crit Care Med 1992;110:847-55.
13. Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder MM. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: Outcome correlations in a prospective study of 200 patients. Am J Med 1989;87:540-6.
14. Korvicks JA, Bryan CS, Farber B, Beam TR, Schenfeld R, Muder RR. Prospective observational study of Klebsiella bacteremia in 230 patients: Outcome for antibiotic combinations versus monotherapy. Antimicrob Agents Chemotherapy 1992;36:2639-44.
15. Knaus WA, Draper EA, Zimmerman JE. APACHE II: A severity of disease classification system. Crit Care Med 1985;13:818-29.
16. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. Am J Infect Control 1988;16:128-40.
17. Rodríguez-Baño J, Ramírez, Santos J, Martínez-Martínez L, Munigin MA, Joyanes P, et al. Risk factors for colonization with Acinetobacter baumannii in the intensive care unit. En: Abstract of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Toronto, Canada, September 28-October 1, 1997 (abstract J-9).
18. Ayats J, Corbella X, Ardanuy C, Domínguez MA, Ricart A, Liñares J, et al. Epidemiologycal significance of cutaneous, pharyngeal, and digestive tract colonization by multiresistant Acinetobacter baumannii in ICU patients. J Hosp Infect 1997;37:287-95.
19. National Committee for Clinical Laboratory Standard. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically approved standard M7-A5. NCCLS, Wayne. PA 2000.
20. Bouvet PJM, Jeajean S. Delineatio of new proteolytic genospecies in the genus Acinetobacter. Res Microbiol 1989;140:291-9.
21. Weaver RE, Actis LE. Identification of Acinetobacter species J Clin Microb 1994;32:1833.
22. Gómez Garcés JL, Fernández Guerrero ML. Significado clínico de las bacteriemias por Acinetobacter calcoaceticus. Enf Infecc Microb Clin 1990;8:606-9.
23. Weinstein MP, Towns MI, Quartey SM, Mirrett S, Reimar LG, Parmigiani G, et al. The clinical significance of positive blood cultures in the 1990s: A prospective comprehensive of microbiology, epidemiology, and outcome of bacteremia and funguemia in adults. Clin Infect Dis 1997;24:584-602.
24. Yinnon AM, Schelesinger Y, Gabbay D, Rudensky B. Analysis of bacteremias: Importance of stratification of microbial susceptibilities by source of patients. J Infect 1997;35:17-23.
25. Gómez J, Simarro E, Baños V, Requena L, Ruiz J, García F, et al. Six-year prospective study of risk and prognostic factors in patients with nosocomial sepsis caused by Acinetobacter baumannii. Eur J Clin Microbiol Infect Dis 1999;18:358-61.
26. Wisplinghoff H, Edmond MB, Pfaller MA, Jones RN, Wenzel RP, Seifert H. Nosocomial bloodstream infections caused by Acinetobacter species in united States Hospitals: Clinical features, molecular epidemiology, and antimicrobial susceptibility. Clin Infect Dis 2000;31:690-7.
27. McDonald LC, Banerje SN, Jarvis WR and the National Nosocomial Infections Surveillance System. Seasonal variatio of Acinetobacter infections; 1987-1996. Clin Infect Dis 1999;29:1133-7.
28. Poutanen SM, Loui M, Simor AE. Risk factors, clinical features and outcome of Acinetobacter bacteremia in adults. Eur J Clin Microb Infect Dis 1997;16: 737-40.
29. García-Garmendia JL, Ortiz-Leyba C, Garnacho-Montero J, Jiménez-Jiménez FJ, Paredes-Paredes C, Barrero-Almodóvar AE, et al. Risk factors for Acinetobacter baumannii nosocomial bacteremia in critically ill patients: a cohort study. Clin Infect Dis 2001;33:939-46.
30. Lortholary O, Fagon JY, Hoi AB, Mahieu G, Gutman L. Colonization by Acinetobacter baumannii in intensive-care patients. Infect Control Hosp epidemiol 1998;19:188-90.
31. Corbella X, Pujol M, Ayats J, Sendra M, Ardanuy C, Domínguez MA, et al. Relelevance of digestive tract colonization in the epidemiology of nosocomial infections due to multirresistant Acinetobacter baumanni. Clin Infect Dis 1996;23:329-34.
32. Wispinghoff H, Perbix W, Seifert H. Risk factors for nosocomial bloodstream infections due to Acinetobacter baumannii: case-control study of adult burn patients. Clin Infect Dis 1999;28:59-66.
33. Moreno S, Vivente T, Armas M, Bernaldo de Quirós JCL, Rodríguez-Creixems, Bouza E. Bacteremia nosocomial por Acinetobacter. Enf Infecc Microb Clin 1990;8:606-9.
34. Raz R, Alroy J, Sobel JD. Nosocomial bacteremia due to Acinetobacter calcoaceticus. Infection 1982;10:168-71.
35. Rodríguez-Baño J. Nosocomial bacteremia due to Acinetobacter baumannii. Rev Medical Microbiology 1999;10:67-77.
36. Cisneros JM, Martín D, Becerril B, Ortiz-Leyba C, Bernabeu-Wittel M, Prados MT, et al. Attributable mortality of nosocomial Acinetobacter baumannii bacteremia. Toronto, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Abstract 1713).
37. Afzal-Sha M, Livermore DM. Worldwide emergence of carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 1999;41:576-7.
38. Urban C, Go E, Mariano N, Berger BJ, Arraham I, Rubin D, et al. Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. J Infect Dis 1993;167:448-51.
39. Jiménez-Mejías ME, Pachón J, Becerril B, Palomino-Nicas J, Rodríguez Cobacho A, Revuelta M. Treatment of multidrug-resistant Acinetobacter baumannii meningitis with ampicilin/sulbactam. J Antimicrob Chemother 1997;24:932-5.
40. Corbella X, Ariza J, Ardanuy C, Vuelta M, Tubau F, Sora M, et al. Efficacy of sulbactam alone and in combination with ampicilin in nosocomial infections caused by multirresistant Acinetobacter baumannii. J Antimicrob Chemother 1998;42:793-802.
41. Levin AS, Barone AA, Penço J, Santos MV, Marinho IS, Arruda EA, et al. Intravenous colistin as therapy for nosocomial infections caused by multi-drug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999;28:1008-11.
42. Buxton AE, Anderson RL, Werdegard D, Atlas E. Nosocomial respiratory tract infection and colonization with Acinetobacter calcoaceticus: epidemiologic characteristics. Am J Med 1978;65:507-13.
43. Peacok JE, Sorrel L, Sottile FD, Price LE, Rutala WA. Nosocomial respiratory tract colonization and infection with aminoglycoside-resistant Acinetobacter calcoaceticus var. anitratus: epidemiologic characteristics and clinical significance. Infect Control Hosp Epidemiol 1988;7:302-8.